Caris Life Sciences, Inc. (CAI)
NASDAQ:CAI
Want to see CAI full AI Analyst Report?
CAI Stock Chart & Stats
$21.15
--
Market closed
$21.15
--
Day’s Range― - ―
52-Week Range$16.28 - $42.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.34M
Market Cap
$5.92B
Enterprise Value$5.56B
Total Cash (Recent Filing)$800.09M
Total Debt (Recent Filing)$378.99M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
May 07, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.28
Shares Outstanding282,579,930
10 Day Avg. Volume1,818,364
30 Day Avg. Volume2,343,836
Financial Highlights & Ratios
PEG Ratio2.83
Price to Book (P/B)78.14
Price to Sales (P/S)55.55
P/FCF Ratio674.37
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue6.84
Enterprise Value/Gross Profit10.31
Enterprise Value/Ebitda1.32K
Forecast
1Y Price Target
$30.83Price Target Upside45.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)0.15
Revenue Forecast (FY)$1.01B
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline And Early Detection DataAnalyst highlights encouraging interim results for the multi-cancer early detection program, which could meaningfully expand future revenue if larger studies validate the initial clinical signals.
New Commercial PartnershipsAnalyst points to a partnership to commercialize a blood-based multi-cancer test and a planned self-pay launch as a new commercial channel that could broaden revenue sources beyond core profiling services.
Revenue Guidance And PricingAnalyst notes management set revenue guidance above market expectations and cited constructive pricing on higher-priced tissue testing, which could sustain revenue per test and lift overall top-line growth.
Bears Say
Accounting Adjustments And Reported GrowthAnalyst warns that some revenue growth was boosted by accounting true-ups from prior periods, raising the risk that headline results may overstate underlying operational momentum.
Commercial Execution And Near-term Profitability RiskAnalyst cautions that planned expansion of the sales force will raise operating expenses and could pressure near-term profitability amid competitor volume volatility and weaker pharma research services.
Valuation And Price TargetAnalyst lowered the price target and trimmed the long-term outlook due to sector valuation compression and more conservative growth assumptions, which could constrain upside for the stock.
Caris Life Sciences, Inc. News
CAI FAQ
What was Caris Life Sciences, Inc.’s price range in the past 12 months?
Caris Life Sciences, Inc. lowest stock price was $16.28 and its highest was $42.50 in the past 12 months.
What is Caris Life Sciences, Inc.’s market cap?
Caris Life Sciences, Inc.’s market cap is $5.92B.
When is Caris Life Sciences, Inc.’s upcoming earnings report date?
Caris Life Sciences, Inc.’s upcoming earnings report date is May 07, 2026 which is in 17 days.
How were Caris Life Sciences, Inc.’s earnings last quarter?
Caris Life Sciences, Inc. released its earnings results on Feb 26, 2026. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.049 by $0.231.
Is Caris Life Sciences, Inc. overvalued?
According to Wall Street analysts Caris Life Sciences, Inc.’s price is currently Undervalued.
Does Caris Life Sciences, Inc. pay dividends?
Caris Life Sciences, Inc. pays a Quarterly dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Caris Life Sciences, Inc. dividends here
What is Caris Life Sciences, Inc.’s EPS estimate?
Caris Life Sciences, Inc.’s EPS estimate is -0.03.
How many shares outstanding does Caris Life Sciences, Inc. have?
Caris Life Sciences, Inc. has 282,579,930 shares outstanding.
What happened to Caris Life Sciences, Inc.’s price movement after its last earnings report?
Caris Life Sciences, Inc. reported an EPS of $0.28 in its last earnings report, beating expectations of $0.049. Following the earnings report the stock price went up 4.678%.
Which hedge fund is a major shareholder of Caris Life Sciences, Inc.?
Currently, no hedge funds are holding shares in CAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Caris Life Sciences, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.83 (45.77% Upside)
$30.83 (45.77% Upside)
Blogger Sentiment
Neutral
CAI Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 5.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
Fundamentals
Return on Equity
24.96%
Trailing 12-Months
Asset Growth
227.48%
Trailing 12-Months
Company Description
Caris Life Sciences, Inc.
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.
CAI Company Deck
CAI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial momentum: very high revenue growth, substantial margin expansion, multiple quarters of positive adjusted EBITDA and free cash flow, a large and growing genomic data asset, and encouraging interim MCED (Caris Detect) results (AUC 0.90, Stage I/II sensitivity 63.1%). Management outlined committed reinvestment in commercial expansion, R&D and MCED capacity while maintaining positive cash flow. Key risks and near-term uncertainties include the interim nature of MCED data (blinded validation and ACHIEVE-2 pending), reimbursement and ASP variability, a meaningful increase in OpEx and CapEx for 2026, and uneven pharma revenue cadence. On balance, the positive financial performance, strong cash position and promising product pipeline outweigh the listed risks.View all CAI earnings summariesCAI Stock 12 Month Forecast
Average Price Target
$30.83
▲(45.77% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---